

DAFTAR PUSTAKA

- Abdelsalam, M., Blais, N., Bossio, E., Bouchard, N., Chu, Q., & Daaboul, N. (2020). Your Comprehensive Guide to Pouch Cells. In *Lung Cancer Canada*.
- Ahyati, S. N., Oktaviyanti, I. K., Yuliana, I., Studi, P., Dokter, P., Kedokteran, F., Patologi, D., Fakultas, A., Biomedik, D., & Kedokteran, F. (2019). Hubungan Jenis Kelamin dan Riwayat Merokok dengan Mutasi Gen EGFR Kanker Paru Tipe Adenokarsinoma. *Homeostasis*, 2 (1), 1–8.
- Amelia, K., Rusli, D., & Hikmah, M. (2022). Evaluasi Penggunaan Obat dan Kesesuaian Dosis Kemoterapi Body Surface Area (BSA) Pasien Kanker Payudara di RSUD Sekayu. *Pharmaceutical Journal of Islamic Pharmacy*, 6(2), 56–62.
- Anwar, J., Elisna, S., & Hudoyo, A. (2009). Kemoterapi Kanker Paru. *Jurnal Respirologi Indonesia*, 29(4), 219–227.
- Araghi, M., Mannani, R., Heidarnejad maleki, A., Hamidi, A., Rostami, S., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., & Akhavan-Sigari, R. (2023). Recent advances in non-small cell lung cancer targeted therapy; an update review. *Cancer Cell International*, 23(1), 1–26. <https://doi.org/10.1186/s12935-023-02990-y>
- Arminsya, M. (2019). *Profil Pasien Kanker Paru dengan Terapi Target di Rumah Sakit dr. Saiful Anwar Malang Tahun 2016-2018*. Universitas Brawijaya.
- Asmara, O. D., Tenda, E. D., Singh, G., Pitoyo, W., Ananda, N. R., Trisnawati, I., Budiyo, E., Thahadian, H. F., Boerma, E. C., Faisal, A., Hutagaol, D., Soeharto, W., Radityamurti, F., Romadhon, Z., Kholis, F. N., & Suryadinata, H. (2023). *Lung Cancer in Indonesia*. 18(9), 1134–1145. <https://doi.org/10.1016/j.jtho.2023.06.010>
- Bonithon-Kopp, C. (2000). How many deaths have been avoided through improvements in cancer survival? *Revue d'épidémiologie et de Santé Publique*, 48(5), 509–510.
- Buana, I., & Harahap, D. A. (2022). Asbestos, Radon, dan Polusi Udara Sebagai Faktor Resiko Kanker Paru pada Perempuan Bukan Perokok. *Jurnal Kedokteran Dan Kesehatan Malikussaleh*, 8(1), 1–16.
- Calderone, R., Nimako, K., Leary, A., Popat, S., & Brien, M. E. R. O. (2011). Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication. *European Journal of Cancer*, 47(11), 1603–1605. <https://doi.org/10.1016/j.ejca.2011.05.008>
- Calvert, B. A. H., Newell, D. R., Gumbrell, L. A., Reilly, S. O., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (2016). Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function. *Journal of Clinical Oncology*, 7(11), 1748–1756.
- Castaneda, J. P., Chaves, J. J., & Parra-medina, R. (2022). Multiple mutations in the EGFR gene in lung cancer : a systematic review. *Transl Lung Cancer Res*, 11(10), 2148–2163. <https://doi.org/10.21037/tlcr-22-235>
- Chadha, V. K. (2006). *Sample size determination in health studies*. 55–62.
- Chantharakhit, C., Ruchakorn, T., Mungkornkaew, S., Amorntrakoon, P., Tassanamethee, S., & Theeratrakul, P. (2022). Efficacy of Premedication Protocol without Ranitidine for Taxane Regimen : A Multicenter Non-

- Randomized Historical Controlled Study. *Asian Pacific Journal of Cancer Prevention*, 23, 1331–1336. <https://doi.org/10.31557/APJCP.2022.23.4.1331>
- Chatelut, E., White-koning, M. L., Mathijssen, R. H. J., Puiisset, F., Baker, S. D., & Sparreboom, A. (2012). Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. *British Journal of Cancer*, 107(7), 1100–1106. <https://doi.org/10.1038/bjc.2012.357>
- Clemmons, A., Gandhi, A., & Healthcare, E. (2021). Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider. *J Adv Pract Oncol*, 810–832.
- Cockcroft, D. W., & Gault, M. H. (1976). Prediction of Creatinine Clearance from Serum Creatinine. *Nephron* 15, 41, 31–41.
- Detterbeck, F. C. (2018). The eighth edition TNM stage classification for lung cancer: What does it mean on main street? *Journal of Thoracic and Cardiovascular Surgery*, 155(1), 356–359. <https://doi.org/10.1016/j.jtcvs.2017.08.138>
- Dipiro, J. T., Yee, G. C., Haines, S. T., Nolin, T. D., Ellingrod, V. L., & Posey, L. M. (2021). *DiPiro's Pharmacotherapy. A Pathophysiologic Approach*.
- Divan, H. A., Bittoni, M. A., Krishna, A., & Carbone, D. P. (2024). Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer. *BMC Cancer*, 24(1), 1–14. <https://doi.org/10.1186/s12885-024-12126-8>
- Duma, N., Santana-Davila, R., & Molina, J. R. (2019). Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. *Mayo Clinic Proceedings*, 94(8), 1623–1640. <https://doi.org/10.1016/j.mayocp.2019.01.013>
- ESMO. (2022). *Kanker Paru Bukan Sel Kecil (KPKBSK)*.
- Faisal, A., Las, L. De, Sanchez, V., Gilbert, L., Copaescu, A. M., & Isabwe, G. A. C. (2022). Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review. *Clinical Reviews in Allergy & Immunology*, 534–547. <https://doi.org/10.1007/s12016-022-08932-2>
- Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021). Cancer statistics for the year 2020: An overview. *International Journal of Cancer*, 149(4), 778–789. <https://doi.org/10.1002/ijc.33588>
- Gold, J. M., & Raja, A. (2023). *Cisplatin, StatPearls [Internet]*. National Library of Medicine.
- Gondhowiardjo, S., Nurhidayat, W., Zhafirah, N. F., Jayalie, V. F., & Sekarutami, S. M. (2023). Cancer Profile in Jakarta : A 5-year Descriptive Study. *Journal of Medical Science*, 11, 17–22. <https://doi.org/10.3889/oamjms.2023.8200>
- Gotfrit, J., Jonker, C., Zhang, T., Goss, G., & Nicholas, G. (2019). Inpatients versus Outpatients with Advanced Non-Small Cell Lung Cancer: Characteristics and Outcomes. In *Cancer Treatment and Research Communications* (Vol. 19). <https://doi.org/10.1016/j.ctarc.2019.100130>
- Greystoke, A., Daumont, M. J., Rault, C., Baltus, H., Ding, P. Q., Emanuel, G., Lucherini, S., Vo, L., Saglimbene, V. M., Ralphs, E., Leal, C., Schoemaker, M. J., Katalinic, A., Waldmann, A., & Cheung, W. Y. (2025). Real-world

- treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany. *BMC Pulmonary Medicine*, 25(1). <https://doi.org/10.1186/s12890-025-03715-9>
- Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., & Rosell, R. (2015). Non-small-cell lung cancer. *Nature Reviews Disease Primers*, 1, 1–16. <https://doi.org/10.1038/nrdp.2015.9>
- Griesinger, F., Korol, E. E., Kayaniyil, S., Varol, N., Ebner, T., & Goring, S. M. (2019). Lung Cancer Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. *Lung Cancer*, 135(June), 196–204. <https://doi.org/10.1016/j.lungcan.2019.07.010>
- Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. (2020). The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. *Cancer Treatment Reviews*, 85(February), 101994. <https://doi.org/10.1016/j.ctrv.2020.101994>
- Gurney, H. (2002). *How to calculate the dose of chemotherapy. 1*, 1297–1302. <https://doi.org/10.1038/sj/bjc/6600139>
- Hasdin, F., Monika, D., & Subakti, B. (2022). Review Article : Mechanisms and Efficacy of Using Diphenhydramine as a Chemotherapy Premedication. *Journal of Pharmaceutical Negative Results*, 13(6), 2268–2276. <https://doi.org/10.47750/pnr.2022.13.S06.295>
- Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. *Nature*, 553(7689), 446–454. <https://doi.org/10.1038/nature25183>
- Ichsan, M. I. N., Bakhtiar, R., Moerad, E. B., & Irawiraman, H. (2020). Hubungan Kadar Carcinoembryonic Antigen (CEA) dengan Subtipe Histologi Kanker Paru di RSUD Abdul Wahab Sjahranie. *Kedokteran Mulawarman*, 7(3), 23–33.
- Ishak, S., Choirunnisa, R., Purnama, A. Y., Achmad, V. S., Mua, E. L., Heryyanoor, Syamil, A., & Ludji, I. D. R. (2023). Metodologi Penelitian Kesehatan. In: Metodologi Penelitian Kesehatan. In S. Bahri (Ed.), *Media Sains Indonesia*. Media Sains Indonesia dan Penulis.
- Jayanti, E. (2013). *Evaluasi Penggunaan Kemoterapi pada Pasien Kanker Paru di Instalasi Rawat Inap RS “X.”* UNIVERSITAS MUHAMMADIYAH SURAKARTA.
- Jeon, H., Wang, S., Song, J., Gill, H., & Cheng, H. (2025). Update 2025 : Management of Non - Small - Cell Lung Cancer. *Lung*, 203(1), 1–15. <https://doi.org/10.1007/s00408-025-00801-x>
- Jordan, K., Feyer, P., Höller, U., Link, H., Wörmann, B., & Jahn, F. (2017). Supportive Treatments for Patients with Cancer. *Clinical Practical Guideline*, 2. <https://doi.org/10.3238/arztebl.2017.0481>
- Karve, S. J., Price, G. L., Davis, K. L., Pohl, G. M., Smyth, E. N., & Bowman, L. (2014). Comparison of demographics, treatment patterns, health care

- utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers. *Health Services Research*, 1–13.
- Kementerian Kesehatan, R. (2023). Panduan Penatalaksanaan Kanker Paru. *Komite Penanggulangan Kanker Nasional*, 10–11.
- Koswara, T., Iriawan, J., & Surya, F. (2022). Karakteristik Karsinoma Paru bukan Sel Kecil dan Hasil Pemeriksaan EGFR di RSUP Dr. Hasan Sadikin Periode Tahun 2018-2020. *Medika Kartika : Jurnal Kedokteran Dan Kesehatan*, 5(2), 150–161.
- Laila, F., Laily, I., Sudarjat, H., & Almas, J. (2025). Review Article : The Comparison of Effectiveness and Side Effects of Pembrolizumab in Combination with Chemotherapy versus Single Chemotherapy in the Treatment of Non-Small Cell Lung Cancer (NSCLC). *Journal of Pharmaceutical and Sciences*, 1336–1354. <https://doi.org/https://doi.org/10.36490/journal-jps.com>
- Lee, A., Yuan, Y., Eccles, L., Chitkara, A., Dalén, J., & Varol, N. (2022). Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies. *Cancer Treatment and Research Communications*, 33(October). <https://doi.org/10.1016/j.ctarc.2022.100648>
- Li, H., & Li, J. (2016). Effectiveness of palliative care for non-small cell lung cancer (Review). *Experimental and Therapeutic Medicine*, 12, 2387–2389. <https://doi.org/10.3892/etm.2016.3621>
- Ma, X., Lin, C., & Zhen, W. (2008). Cancer care in China: A general review. *Biomedical Imaging and Intervention Journal*, 4(3). <https://doi.org/10.2349/bijj.4.3.e39>
- Mitsudomi, T., Suda, K., & Yatabe, Y. (2013). Surgery for NSCLC in the era of personalized medicine. *Nature Reviews Clinical Oncology*, 10(4), 235–244. <https://doi.org/10.1038/nrclinonc.2013.22>
- Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008). Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. *Mayo Clinic Proceedings*, 83(5), 584–594. <https://doi.org/10.4065/83.5.584>
- Montagne, F., Guisier, F., Venissac, N., & Baste, J. (2021a). The Role of Surgery in Lung Cancer Treatment : Present Indications and Future Perspectives — State of the Art. *Cancers*, 13, 1–24. <https://doi.org/10.3390/cancers13153711>
- Montagne, F., Guisier, F., Venissac, N., & Baste, J. M. (2021b). The role of surgery in lung cancer treatment: Present indications and future perspectives—state of the art. *Cancers*, 13(15), 1–24. <https://doi.org/10.3390/cancers13153711>
- Mustafa, M., Azizi, A. J., Iilzam, E., Nazirah, A., Sharifa, S., & Abbas, S. (2016). Lung Cancer: Risk Factors, Management, And Prognosis. *IOSR Journal of Dental and Medical Sciences*, 15(10), 94–101. <https://doi.org/10.9790/0853-15100494101>
- Nasution, V. S., Wahyuni, S., Dalimunthe, G. I., & Lubis, M. S. (2025). Analisis Penggunaan Obat Kemoterapi Kanker Paru di RSUD Dr. Pirngadi Kota Medan. *Jurnal Farmasi, Sains, Dan Kesehatan*, 4(2), 201–216.
- NCCN. (2024). *Metastatic Non-Small Cell Lung Cancer*.
- NCCN. (2025a). *NCCN Clinical Practice Guidelines in Oncology : Non-Small Cell Lung Cancer*.

- NCCN. (2025b). *Palliative Care*.
- Novello, S. (2018). Alectinib in the treatment of ALK-positive non-small cell lung cancer : an update on its properties , efficacy , safety and place in therapy. *Therapeutic Advances in Medical Oncology Review*, 10, 1–12. <https://doi.org/10.1177/1758835918789364>
- Oktariyanto, E. E., Yasin, N. M., & Puspitasari, I. (2024). A Study on Lung Cancer Chemotherapy Regimen Administration at Universitas Gadjah Mada Academic Hospital. *Academic Hospital Jurnal*, 6(2), 43–51.
- Orosz, Z., & Kovács, Á. (2024). The role of chemoradiotherapy and immunotherapy in stage III NSCLC. *Pathology and Oncology Research*, 30(April), 1–6. <https://doi.org/10.3389/pore.2024.1611716>
- Pranyoto, R. A. P. (2021). Penelitian BAB 3. *Journal*, 1–23.
- Qi, C., Sun, S., & Xiong, X. (2022). From COPD to Lung Cancer : Mechanisms Linking , Diagnosis , Treatment , and Prognosis. *International Journal of Chronic Obstructive Pulmonary Disease*, 17(September), 2603–2621.
- Reck, M., Popat, S., Reinmuth, N., Ruyscher, D. De, Kerr, K. M., & Peters, S. (2015). Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *ESMO Updated Clinical Practice Guidelines*, 25(May 2014), iii27–iii39. <https://doi.org/10.1093/annonc/mdu199>
- Roato, I. (2014). Bone metastases: When and how lung cancer interacts with bone. *World Journal of Clinical Oncology*, 5(2), 149–156. <https://doi.org/10.5306/wjco.v5.i2.149>
- Rodak, O., Díaz, M. D. P., Olbromski, M., Podhorska-Okołów, M., & Dzięgieł, P. (2021). Current Landscape of Non-Small Cell Lung Cancer : Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. *Cancers*, 13, 4705. <https://doi.org/10.3390/cancers13184705>
- Rusdi, N. K., Sari, E. N., & Wulandari, N. (2023). Ketepatan Obat, Dosis, dan Potensi Interaksi Obat pada Pasien Kanker Paru di Rumah Sakit X Jawa Barat Periode 2019-2021. *Jurnal Sains Dan Kesehatan*, 5(3), 313–323. <https://doi.org/10.25026/jsk.v5i3.1754>
- Sari, L., & Purwanto. (2016). Mutasi EGFR pada Non-Small Cell Lung Cancer. *Indonesian Journal of Cancer*, 10(4), 131–136.
- Sari, S., Andayani, T. M., Endarti, D., & Widayati, K. (2019). Efikasi Afatinib dan Gefitinib pada Pasien Non-small Cell Lung Cancer EGFR Mutasi Positif: Tinjauan Sistematis. *Indonesian Journal of Clinical Pharmacy*, 8(4), 289. <https://doi.org/10.15416/ijcp.2019.8.4.289>
- Shaw, A. T., Engelman, J. A., Shaw, A. T., & Engelman, J. A. (2013). ALK in Lung Cancer : Past , Present, and Future. *Journal of Clinical Oncology*, 31(8), 1105–1111. <https://doi.org/10.1200/JCO.2012.44.5353>
- Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., Fujisawa, T., Feng, Z., Roth, J. A., Minna, J. D., & Gazdar, A. F. (2005). Clinical and Biological Features Associated With. *Journal of the National Cancer Institute*, 97(5), 339–346. <https://doi.org/10.1093/jnci/dji055>
- Shinde, A., Li, R., Kim, J., Salgia, R., Hurria, A., & Amini, A. (2018). Stereotactic

- body radiation therapy (SBRT) for early-stage lung cancer in the elderly. In *Seminars in Oncology* (Vol. 45, Issue 4). Elsevier Inc. <https://doi.org/10.1053/j.seminoncol.2018.06.002>
- Stage, T. B., Bergmann, T. K., & Kroetz, D. L. (2021). Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review. *Clin Pharmacokinet*, 57(1), 7–19. <https://doi.org/10.1007/s40262-017-0563-z>
- Stratton, S. J. (2023). Population Sampling: Probability and Non-Probability Techniques. *Prehospital and Disaster Medicine*, 38(2), 147–148. <https://doi.org/10.1017/S1049023X23000304>
- Sugiyono, P. D. (2023). Metode Penelitian Kuantitatif Kualitatif dan R&D. In D. I. Sutopo (Ed.), *Educacao e Sociedade* (Kedua, Cet, Vol. 1, Issue 1). Alfabeta Bandung.
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). *Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries*. 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Tan, V. S., Tjong, M. C., Chan, W. C., Yan, M., Delibasic, V., Darling, G., Davis, L. E., Doherty, M., Hallet, J., Kidane, B., Mahar, A., Mittmann, N., Parmar, A., Tan, H., Wright, F. C., Coburn, N. G., & Louie, A. V. (2023). Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis. *Current Oncology*, 30, 3461–3472. <https://doi.org/10.3390/currncol30030262>
- Tarawneh, N., Hussein, S. A., & Abdalla, S. (2025). Repurposing Antiepileptic Drugs for Cancer: A Promising Therapeutic Strategy. *Journal of Clinical Medicine*, 1–26. <https://doi.org/10.3390/jcm14082673>
- Tomasini, P., Barlesi, F., Masciaux, C., & Greillier, L. (2016). Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. *Therapeutic Advances in Medical Oncology Review*, 8(3), 198–208. <https://doi.org/10.1177/1758834016644155>
- Trybus, E. (2024). H1 Antihistamines — Promising Candidates for Repurposing in the Context of the Development of New Therapeutic Approaches to Cancer Treatment. *MDPI Journal Cancers*, December, 1–25. <https://doi.org/10.3390/cancers16244253>
- Upadhyay, A., Yadav, K. S., & Misra, A. (2021). Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. *Expert Opinion on Drug Delivery*, 18(1), 73–102. <https://doi.org/10.1080/17425247.2021.1825377>
- Venuta, F., Diso, D., Onorati, I., Anile, M., Mantovani, S., & Rendina, E. A. (2016). Lung cancer in elderly patients. *J Thorac Dis*, 8(I), 908–914. <https://doi.org/10.21037/jtd.2016.05.20>
- Williams, A. C., Grant, M., Tiep, B., Kim, J. Y., & Hayter, J. (2013). Dyspnea Management in Early Stage Lung Cancer: A Palliative Perspective. *J Hosp Palliat Nurs*, 14(5). <https://doi.org/10.1097/NJH.0b013e31825e4250>
- Wu, K., Wong, E., & Chaudry, S. (2018). *Lung Cancer*. <https://www.nhs.uk/conditions/Lung-Cancer/Symptoms/>. <https://www.nhs.uk/conditions/lung-cancer/symptoms/>



- Wulandari, A., Monalisa, S., & Zaini, J. (2019). Analisis Biaya Kemoterapi Lini Pertama Pada Pasien Kanker Paru di Rumah Sakit Persahabatan Jakarta Timur Periode Tahun 2016. *Sainstech Farma*, 12, 167–186.
- Xie, X., Wu, Y., Luo, S., Yang, H., Li, L., Zhou, S., Shen, R., & Lin, H. (2017). Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors : a Meta-Analysis of 6 Randomized Controlled Trials. *Asian Pacific Journal of Cancer Prevention*, 18, 479–484. <https://doi.org/10.22034/APJCP.2017.18.2.479>
- Yao, D., Zhou, H., & Chen, Q. (2026). Efficacy of prophylactic adoption of recombinant human granulocyte colony-stimulating factor in advanced lung cancer patients after chemotherapy. *Tissue and Cell*, 99(December 2025), 103288. <https://doi.org/10.1016/j.tice.2025.103288>
- Yusuf, S. D. F., Al Afifah, R. N., & Ramadhani, S. (2024). Eksplorasi Imunoterapi dalam Pengobatan Kanker Paru. *Health & Medical Sciences*, 2(1), 13. <https://doi.org/10.47134/phms.v2i1.239>
- Zheng, M. (2016). Classification and Pathology of Lung Cancer. *Surgical Oncology Clinics of North America*, 25(3), 447–468. <https://doi.org/10.1016/j.soc.2016.02.003>